The top three gynecological device companies in 2026 are Hologic, Meditrina and Axora Medical, ranked by U.S. market share in iData Research’s latest gynecological device report.
Hologic, the market leader, became a private company in April 2026 when Blackstone and TPG completed their acquisition.
That deal, along with Axora Medical’s purchase of Minerva Surgical’s business assets, has reshaped the top of a U.S. market that iData Research valued at $1.56 billion in 2025.
This guide covers who leads, which devices drive their positions and what the Hologic buyout means for gynecology.
[[cta-top]]
Table of Contents
➜ Who are the top gynecological device companies in 2026
➜ Why Hologic leads the gynecological device market
➜ What Hologic going private means for gynecological devices
➜ What makes Meditrina a top gynecological device company
➜ How Axora Medical became a top gynecological device company
➜ Which companies lead other gynecological device segments
Key Takeaways
- Hologic, Meditrina and Axora Medical lead the U.S. gynecological device market by 2025 market share.
- Blackstone and TPG completed their acquisition of Hologic on April 7, 2026, taking the company private.
- Axora Medical acquired the business assets of Minerva Surgical in January 2026.
- iData Research values the U.S. gynecological device market at $1.56 billion in 2025, growing at a 2.1% CAGR to $1.8 billion.
Who are the top gynecological device companies in 2026
The top gynecological device companies are Hologic, Meditrina and Axora Medical.
That ranking comes from iData Research’s 2026 report on the U.S. gynecological device market, which measures 2025 market share.
Hologic ranks first on the strength of its endometrial ablation and tissue removal systems.
Meditrina ranks second through its hysteroscopy business.
Axora Medical ranks third, and its January 2026 deal for Minerva Surgical’s assets broadened its portfolio.
iData Research forecasts the market to grow from $1.56 billion in 2025 to $1.8 billion by 2032.
Procedure volume is rising too, from about 3.8 million gynecological procedures in 2025 to about 4.1 million in 2032.
Many smaller companies have entered the market, especially in uterine manipulators and endoscopes, which keeps pricing highly competitive.
Why Hologic leads the gynecological device market
Hologic was the leading company in the U.S. gynecological device market in 2025, according to iData Research.
Its NovaSure radiofrequency endometrial ablation device is a core part of that lead.
The MyoSure Tissue Removal System is another pillar, valued for short procedure times and a low risk profile.
Hologic ranks first in three segments: global endometrial ablation, hysteroscopic morcellators and fluid management.
In January 2025, Hologic closed its $350 million acquisition of Gynesonics, maker of the Sonata System for treating certain symptomatic uterine fibroids without incisions.
iData Research expects Hologic to maintain its market dominance in the coming years.
What Hologic going private means for gynecological devices
Blackstone and TPG first announced the Hologic deal on October 21, 2025, and completed it on April 7, 2026.
Shareholders received $76 per share in cash plus a contingent value right worth up to $3 per share, according to Hologic’s closing announcement filed with the SEC.
Those contingent payments are tied to revenue goals for Hologic’s Breast Health business in fiscal 2026 and 2027.
Hologic’s stock stopped trading and was delisted from Nasdaq.
A subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC also made significant minority investments.
Joe Almeida, the former head of Baxter International and Covidien, became CEO, succeeding Stephen MacMillan.
The buyout covers all of Hologic, including its diagnostics and breast health businesses, not only gynecology.
For gynecology, it means NovaSure, MyoSure and Sonata now sit inside a privately owned market leader.
With Hologic off the public market, independent share data such as iData Research’s rankings is a practical way to track its gynecology position year to year.
[[cta-mid]]
What makes Meditrina a top gynecological device company
Meditrina was the second leading gynecological device company in the U.S. in 2025.
The company earned that spot through its presence in the hysteroscopic device market, where it has been active since 2019.
Its Aveta hysteroscopy system combines high-definition vision, integrated fluid management and single-use resecting devices.
In May 2024, Meditrina received clearance for its Gen 2 bipolar RF system and the Aveta Glo device.
Meditrina ranks second in gynecological endoscopes and third in hysteroscopic morcellators.
Clinical evidence supports demand for hysteroscopy outside the operating room.
A 2025 systematic review on office versus operating room hysteroscopy found pooled success rates of about 95% and complication rates of about 0.6% for office procedures.
A 2025 clinical practice review of office hysteroscopy reported that smaller-diameter hysteroscopes reduce procedural pain.
iData Research expects Meditrina to keep expanding its market share.
How Axora Medical became a top gynecological device company
Axora Medical was the third-leading gynecological device company in the U.S. in 2025.
In January 2026, Axora Medical acquired the business assets of Minerva Surgical, a provider of minimally invasive technologies for abnormal uterine bleeding.
The deal brought Axora an extensive portfolio, including the Minerva ES Endometrial Ablation System.
Axora Medical holds share in endometrial ablation, gynecological endoscopes and fluid management.
It ranks second behind Hologic in both global endometrial ablation and fluid management.
iData Research expects Axora Medical to see minor expansion of its market share over the coming years.
Which companies lead other gynecological device segments
Several companies outside the top three lead individual segments.
Cooper Surgical leads gynecological endoscopes, HSG catheters and uterine manipulators.
Olympus leads gynecological resection electrodes, and Merit Medical Systems leads uterine fibroid embolization devices.
Laborie Medical leads pelvic floor electrical stimulation devices, while Coloplast leads sacrocolpopexy mesh.
Medtronic ranks second in hysteroscopic morcellators.
In June 2026, Medtronic submitted 510(k) filings to the FDA to expand its Hugo Robotic-Assisted Surgery System into gynecologic and general surgery, a shift covered in our look at robotic vs laparoscopic surgery adoption in 2026.
Single-use devices are also gaining ground, especially gynecological endoscopes, as contamination concerns rise.
For the wider minimally invasive picture, see our ranking of the top laparoscopic device companies in 2026.
Frequently asked questions
Who is the largest gynecological device company?
Hologic is the largest gynecological device company in the U.S. by 2025 market share, according to iData Research.
Who owns Hologic now?
Funds managed by Blackstone and TPG own Hologic, with significant minority investments from a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC.
How much did Blackstone and TPG pay for Hologic?
The deal was valued at up to $79 per share, made up of $76 in cash and a contingent value right worth up to $3.
How big is the U.S. gynecological device market?
iData Research values the U.S. gynecological device market at $1.56 billion in 2025 and forecasts $1.8 billion by 2032, a 2.1% CAGR.
What gynecological devices does Hologic make?
Hologic’s gynecology portfolio includes the NovaSure endometrial ablation device, the MyoSure Tissue Removal System and the Sonata System from Gynesonics.
Which companies are gaining gynecological device market share?
iData Research expects Meditrina to keep expanding its share and Axora Medical to see minor gains, while Hologic maintains its lead.
[[cta-bot]]
